FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.

Also called NCT02652806

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 305 participants (enrolled count) (from the registry)
Sponsor
  • Kyntra Bio Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02652806
Other papers using this trial's data
  • Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis The New England journal of medicine, 2019-09-12 DOI, PubMed 31340116

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02652806. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2017-01-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
Condition
Anemia
Intervention (Drug)
FG-4592
Intervention (Drug)
Epoetin Alfa
Lead sponsor
Kyntra Bio (class: industry)

Record details

Record id
cardio:ct-nct02652806
Content hash
3f18296202e414b3bc5f3b844b464fb76852fb3d5573a458cdc4ea873b3dc2fb